Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rad51 Degradation: Role in Oncolytic Virus—Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma

10 Feb 2017

Abstract excerpt

Background: Clinical success of poly(ADP-ribose) polymerase inhibitors (PARP i ) has been limited to repair-deficient cancers and by resistance. Oncolytic herpes simplex viruses (oHSVs) selectively kill cancer cells, irrespective of mutation, and manipulate DNA damage responses (DDR). Here, we explore potential synthetic lethal-like interactions between oHSV and PARP i . Methods: The efficacy of combining PARP i...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Herpesvirus Infections and Treatments
Share to PARP inhibition in cancer therapy
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28376211
DOI: 10.1093/jnci/djw229

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rad51 Degradation: Role in Oncolytic Virus—Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in GlioblastomaPMID 28376211Read ↗

Olaparib Enhances the Efficacy of Third‐Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc‐Induced ApoptosisSemantic proximity Read ↗

Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screeningSemantic proximity Read ↗

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation TherapySemantic proximity Read ↗

PARP inhibition and immunotherapy: a promising duo in fighting cancerSemantic proximity Read ↗

Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP InhibitorsSemantic proximity Read ↗

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.Semantic proximity Read ↗

Therapeutic Application of PARP Inhibitors in Neuro-Oncology.Semantic proximity Read ↗

Polθ Inhibitor (ART558) Demonstrates a Synthetic Lethal Effect with PARP and RAD52 Inhibitors in Glioblastoma CellsSemantic proximity Read ↗

PARP Inhibitor Counteracts Temozolomide Resistance in Glioblastoma MultiformeSemantic proximity Read ↗

Enhanced efficacy of combined HDAC and PARP targeting in glioblastomaSemantic proximity Read ↗

Selective Inhibition of Parallel DNA Damage Response Pathways Optimizes Radiosensitization of Glioblastoma Stem-like CellsSemantic proximity Read ↗

AAV Kills Dividing Cells by Depleting PARP1 and Other DNA Damage Response ProteinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.